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Heterologous  anti-lymphocyte serum  (ALS)  1 is  a  potent  and  effective im- 
munosuppressive agent. Administration of ALS decreases the ability of treated 
animals to reject allografts (1  4)  and to produce humoral antibody when  im- 
munized with certain antigens such as sheep red blood cells (SRBC)  (2, 3, 5, 6). 
The  production  of  antibody against  SRBC  requires  a  synergistic interaction 
between cells of thymus  and marrow  origin (7,  8)  and  Martin  and  Miller (9) 
have shown that thymus-derived spleen cells are inactivated when ALS treat- 
ment is used to depress the ability of a mouse to produce anti-SRBC antibody. 
We have recently reported  (10)  that cells of marrow  origin appear to be like- 
wise  affected. These preliminary results have  been extended and  the findings 
obtained form the subject of this communication. 
Materials and Methods 
Animals  Used.--A local farm horse was used for production of ALS, and male CBA mice 
(18-22 g body weight) served as skin graft donors. All other animals used in these experiments 
were male C57BL/6J mice (20-25 g body weight). The mice were obtained from the Jackson 
Laboratory, Bar Harbor, Maine. 
Preparation  o[ ALS.--A  single  pool of  horse  anti-mouse lymphocyte serum  was  used 
throughout these experiments.  For the preparation of ALS, a horse was repeatedly injected 
with a mixture of thymus and lymph node cells obtained from male C57BL/6J mice. Each 
inoculum contained 109 cells and injections were given subcutaneously on days 0, 3, 6, and 9 
and intravenously on days 10, 14, and 21. The horse was bled on day 29 and the serum ob- 
tained was stored in portions of 2 ml at  -20°C.  Before use,  all ALS was decomplemented 
(heating at 56°C for 30 min) and absorbed with an equal volume of packed SRBC to remove 
natural anti-SRBC antibodies. 
Skin Grafting of Mice.--The method employed  and the criteria used  for  assessing graft 
rejection have been previously described  (11). 
Immunization  with  SRBC  and  Determination of Hemagglutinin  Titers.--SRBC  were  ob- 
tained from freshly bled sheep and stored at 4°C in Alsever's solution. The cells were always 
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used within a week after collection. For purposes of immunization, the cells were washed three 
times in 0.9% NaCI,  suspended in TC  199  (Difco Laboratories, Inc.,  Detroit,  Mich.), and 
intravenously injected into mice. Each mouse received 0.5 ml of a  2% suspension of SRBC. 
Hemagghitinin titers were determined 7 days after immunization using a technique which we 
previously described (12). The tlter recorded was the dilution in the last well in which the cell 
pattern differed from the buttons of cells present in the control wells. 
Preparation o.f Cell Suspenslons.--Thymus and spleen cell suspensions were prepared by a 
previously described method (11). For preparation of marrow cell suspensions, the long bones 
were removed from mice  and after their ends had been cut off,  tile marrow cavities were 
flushed out with TC 199. Before use, the resulting cell suspension was passed through a stain- 
less steel mesh to remove debris. 
Statistical Analyses.--To determine the ranges of the 95% confidence limits of the means, 
the t value for the appropriate degrees of freedom was multiplied by the standard error of the 
mean (13). 
Plan of Experiments.--The basic experimental model used has been previously described 
(14) and derives from the work of Santos and Owens (15).  C57BL/6J mice were killed 24 hr 
after the last of four successive daily subcutaneous injections of 0.5 ml ALS. A suspension of 
cells from the spleens of these animals was mixed with SRBC and intravenously injected into 
syngenelc mice rendered immunologically anergic by the intraperitoneal injection of cyclo- 
phosphamide  (250 mg/kg body weight) 6-8 hr earlier. Serum hemagghitinln titers were de- 
termined 7 days later. 
Titers produced by cyclophosphamide  (CY)-treated mice injected with SRBC  and 2  X 
107 normal spleen ceils were much higher than those found when the CY-treated mice received 
SRBC and 2 X  107 spleen cells from mice previously given ALS. In subsequent experiments 
attempts were made to see if the depressed titers in this latter group could be elevated to 
normal levels by intravenously injecting the CY-treated mice with normal syngeneic thymus 
and/or marrow cells,  in  addition to  SRBC  and spleen cells from ALS-treated donors.  The 
thymus and marrow cells were injected into a different vein immediately after the injection of 
spleen cells. 
SRBC and spleen ceils were always injected 6-8 hr after the mice had received CY.  Be- 
cause of the danger of acute  death from pulmonary emboli, not more than a  total of  l0  s 
nucleated  thymus  and  marrow  cells were  intravenously injected  on  any one  occasion.  If 
larger numbers of thymus and marrow cells had to be injected, they were given in divided 
doses of 0.8-1  X  l0  s cells each, at 8-12 hr intervals. The first injection of l0  s cells was given 
at the same time as the SRBC and spleen cells,  and all subsequent injections were completed 
within the next 18 hr. 
In a final series of experiments, SRBC and mixtures of thymus and marrow cells from both 
untreated and ALS-treated donors were adoptively transferred to mice previously given CY. 
These  experiments were  done  to  determine whether,  and  to  what  degree,  ALS  treatment 
altered the immunological competence of cells located within the thymus and marrow. 
RESULTS 
Suppression of Immune Responses by ALS.--The ALS  used in these experi- 
ments  was  a  moderately  good immunosuppressive  agent. The median survival 
time of CBA grafts on male C57BL/6J  mice given 0.5 ml of ALS subcutaneously 
on  days  +1,  +4,  +7,  and  +10  after  grafting  was  17  days,  with  a  range  of 
14-23  days.  All grafts  on untreated  or  normal  horse serum-treated  recipients 
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Table I  shows that the ALS used was also capable of decreasing the immune 
response to SRBC. Administration  of ALS for 3  consecutive days before im- 
munization  with  SRBC  significantly  depressed  the  serum  hemagglutinin 
response of treated  animals. A  still greater depression of serum hemagglutinin 
levels was found when  mice received 4  days of pretreatment  with ALS. This 
latter dose of ALS reduced the 19S plaque-forming cell (PFC) responses in the 
spleens of treated animals to background levels. 
Antibody Production by C Y-  Treated Mice Given S RBC and Normal S yn  geneic 
Lymphoid Cells.--Table  II shows that hemagglutinin  titers  produced by CY- 
treated  mice  given  SRBC  were  significantly  lower  than  those  produced  by 
mice given SRBC but not CY. Titers could be raised to the levels found in the 
TABLE I 
ttemagglutinin Titers Produced by Mice Given SRBC after Injections of ALS 
Mice received  Serum given on days* 
No. of mice producing hemagglutinin titers:~ of 
0  2  3  4  5  6  7  8  9  >9 
Nil 
Normal horse  --4, -- 3, -- 2, -- 1 
serum 
ALS  --2, --1 
ALS  --3, --2, --1 
ALS  --4, --3, --2, -- 1 
1  4  3  4  4 
4  3  2  3 
2  20 
10 
16 
Male C57BL/6J mice intravenously  injected with 0.5 ml of a 2% suspension of SRBC 
24 hr after the last injection of serum. Hemagglutinin titers determined 7 days later. 
* Serum given as subcutaneous  injections of 0.5 ml each time. SRBC were injected  on 
day 0. 
:~ Titers  expressed in terms of log2 of their reciprocals. 
latter group if the CY-treated mice received a mixture of SRBC and 2  X  l0  T 
normal syngeneic spleen cells. Similar serum hemagglutinin levels resulted when 
the  CY-treated  mice were  given  SRBC  and  a  mixture  containing 1.2  X  108 
normal  thymus  and  1.2  X  l0  s  normal  marrow  cells.  Mixtures  containing 
fewer thymus and marrow cells produced correspondingly smaller  amounts  of 
antibody.  Titers  were  very  low  when  large  numbers  of  either  thymus  (1.2 
X  l0  s) or marrow cells  (1.2  X  l0  s)  alone were  given  to the  CY-treated  ani- 
mals. 
A  synergistic  interaction  between  normal  thymus  and  marrow  cells  was 
demonstrable when a  mixture  containing SRBC and these two cell types was 
given  to  CY-treated  mice.  Serum hemagglutinin  titers  produced  by  animals 
given the mixture were invariably higher than the sum of the titers produced 
by mice given  SRBC  and  thymus  or marrow cells  alone  in  that  experiment. 
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log2  of  their  reciprocals.  Hence,  summation  is  not a  simple arithmetical proc- 
ess.  For example, 4  +  4  =  5.) 
Antibody  Production  by  CY-Treated  Mice  Given  SRBC  and  Spleen  Cells 
TABLE  II 
Hemagglutlnln Tilers Produced by  Cyclophosphamlde (CY)-Treated C57BL/6J Mice Given 
SRBC and Normal Syngeneic Spleen, Thymus, and Marrow Cells 
Hemagglutinin tilers*  Experi-  No. of 
ment  CY-treated mice given  mice  95% confidence 
No.  Mean  limits of means 
SRBC  (no CY)  14  9.6 
SRBC  12  0.4 
SRBC +  0.5 X  107 spleen cells  8  0.4 
SRBC +  1 )<  107 spleen cells  8  5.0 
SRBC +  2  X  107 spleen cells  12  9.1 
SRBC +  3.5 X  107 spleen cells  8  9.4 
SRBC +  2 )<  107 inactivated spleen cells  12  0.5 
SRBC q- 2 X  107 spleen cells  7  11.1 
SRBC q- 2 X  107 thymus and 2 X  107 mar-  8  5.3 
row ceils 
SRBC +4X  107 thymusand4 X  107mar  -  8  6.0 
row cells 
SRBC +  2 X  107 spleen cells  8  11.4 
SRBC +  8 X  107 thymus cells  8  2.6 
SRBC +  8  X  107 marrow cells  7  3.5 
SRBC +  8X 107thymusand8 X  107mar  -  8  7.9 
row ceils 
SRBC -1- 2  X  10 7 spleen cells  8  9.5 
SRBC -t-  1.2 X  l0 s thymus cells  8  3.6 
SRBC -t-  1.2  X  10 s marrow cells  7  3.6 
SRBC -t- 1.2X  10s thymus and 1.2 X  10 s  7  9.2 
marrow cells 
8.3-10.9 
0.2-0.6 
&0.9 
3.7-6.3 
8.3-9.9 
8.~10.0 
~1.5 
10.8-11.4 
4.&6.6 
4.5-7.5 
10.4-12.4 
1.6-3.6 
2.4--4.6 
5.5-10.3 
8.9-10.1 
3.0-4.2 
2.5-4.7 
8.4-10.0 
Mice were given CY (250 mg/kg body weight) intraperitoneally 6-8 hr prior to  intrave- 
nous injection of SRBC and syngeneic lymphoid cells.  Serum hemagglutinin titers were deter- 
mined 7 days later. 
*Titers expressed in terms of log2 of their reciprocals.  All  mice received 0.5 ml of a  2% 
suspension of SRBC. 
from ALS-Treated Donors.--Table III  shows that spleen cells from ALS-treated 
animals  are  deficient  in  their  ability  to  produce  anti-SRBC  antibody.  These 
immunological  deficits  were  only  demonstrable  after  3  days  of  pretreatment 
with ALS (Table III), and Table I  shows that this was the minimum  amount  of 
ALS required to significantly depress the serum hemagglutinin response of mice 
immunized with SRBC. H.  ~.JEEJEEBHOY  967 
Antibody Production by CY-Treated Mice Given SRBC, Spleen Cells from ALS- 
Treated  Animals,  and Normal Thymus and/or Marrow Cells.--The  next series 
of experiments  (Table IV) were performed in order to determine whether  the 
immunological  deficits  which  appeared  in  the  spleens  of  animals  given  ALS 
might have been due to the inactivation of cells which were functionally similar 
to thymus  and/or  marrow  cells.  The  additional  injection  of a  mixture  con- 
taining normal thymus and marrow cells significantly raised the serum hemag- 
glutinin  levels found when  CY-treated  mice were  given  SRBC  and  2  X  10  7 
spleen cells from ALS-trea'ted donors. If the mixture contained 8 X  10  7 thymus 
cells and 8 X  10  7 marrow cells, hemagglutinin titers produced by the immuno- 
TABLE III 
Hemagglutlnln Titers Produced by Cyclophosphamide (CY)-Treated C57BL/6J  Mice Given 
SRBC and Syngeneic Spleen Cells  from ALS-Treated Donors 
Experi-  No. of  Hemagglutinin titers~: 
CY- 
ment  Spleen cell donors received  Serum given on days*  treated  Mean  95% confidence 
no.  recipients  limits of means 
Nil  --  8  12.2  11.6-12.8 
Normal horse serum  --4, --3, --2, --1  8  11.8  11.1-12.5 
ALS  --1  8  11.4  10.7-12.1 
Nil  --  8  11.1  10.6-11.6 
ALS  --2, --1  8  10.7  10.1-11.3 
ALS  --3, --2, --1  8  4.1  3.7-4.5 
Mice were intravenously injected with 0.5 ml of a 2% suspension of SRBC containing 2 X 
107 syngeneic spleen cells 6-8 hr after intraperitoneal injection of CY (250 mg/kg body weight). 
Hemagglutinin titers were determined 7 days later. 
* Serum given as subcutaneous injections of 0.5 ml each time. Cells transferred 24 hr after 
the last injection. 
Titers  expressed in terms of logs of their reciprocals. 
logically  anergic  recipients  were  similar  to  those  found  after  their  injection 
with SRBC and 2 X  10  7 normal spleen ceils. Mixtures containing fewer thymus 
and marrow cells were correspondingly less effective. Marrow cells (1.2  X  10  8) 
alone were completely ineffective and only a partial elevation of hemagglutinin 
titers  to normal levels was found when  the  inoculum contained  thymus cells 
(1.2  X  10  s)  alone.  Titers  produced by CY-treated  mice given  SRBC,  spleen 
ceils  from ALS-treated  donors,  and  normal  thymus  and  marrow  cells  were 
always higher  than  the  sum of the  titers  separately  produced by the  groups 
given  SRBC  and  either  spleen  cells  from  ALS-treated  animals  or  normal 
thymus and marrow cells. This suggests that there was a synergistic interaction 
between  spleen  cells  from ALS-treated  donors  on  the  one  hand  and  normal 
thymus and marrow cells on the other. A  synergy was also demonstrable when 968  EFFECT  OF  ANTI-LYMPHOCYTE  SERUM  ON  LYMPHOCYTES 
the  CY-treated  recipients  of SRBC  and  spleen cells from ALS-treated  donors 
were  given  1.2  X  10 s  normal  thymus  cells  alone  (Table  IV,  experiment  1). 
A n tibody Production by CY-Treated Mice Given SRBC and Mixtures of Thymus 
TABLE IV 
IIemagglutinin Titers Produced by  Cydophosphamide (CY)-Treated C57BL/6J Mice Given 
Normal Syngeneic Thymus and~or Marrow Cells in Addition to SRBC and Spleen 
Cells from Syngeneic ALS-Treated Donors 
Hemagglutinin titers$  Experi-  No. of 
ment  CY-treated hosts received  SRBC and*  recipients  Mean  95% confidence 
no.  limits of means 
Normal spleen cells (2 X  10 7)  8  10.1 
Normal thymus cells (1.2 X  10 8)  8  1.4 
ALS spleen ceils (2 X  10 7)  7  2.4 
ALS spleen ceils (2  X  10 7)  +  normal thymus  8  3.4 
cells (2 X  10 7) 
ALS spleen cells (2  X  10 7)  +  normal thymus  8  5.5 
cells (1.2 X  10 8) 
Normal spleen cells (2 X  107)  8  11.3 
Normal marrow cells (1.2 X  108)  8  3.9 
ALS spleen cells (2)<  107)  7  2.0 
ALS spleen cells (2  X  107) +  normal marrow  8  3.9 
cells (1.2 X  l0 s) 
9.3-10.9 
0.4-2.4 
1.7-3.1 
2.1-4.7 
4.9-6.1 
8.9-13.7 
2.8-5.0 
1.0-3.0 
2.2-5.6 
3  Normal spleen cells (2 X  107)  8  13.6  12.2-15.0 
Normal  thymus  (4)<  107) +  normal  marrow  8  6.1  5.4-6.8 
cells (4 X  107) 
ALS spleen cells (2 X  107)  8  3.1 
ALS spleen cells (2  X  107) +  normal  thymus  8  9.4 
(4 X  107) and normal marrow cells (4 X  107) 
2.2-4.0 
8.3-10.5 
4  Normal spleen cells (2)<  10 7)  8  11.5  11.0-12.0 
Normal  thymus  (8  X  10 7)  +  normal  marrow  8  6.1  5.2-7.0 
cells (8 X  107) 
ALS spleen cells (2)<  107)  8  4.0 
ALS spleen cells (2  X  107) +  normal  thymus  7  10.3 
(8 X  107) +  normal marrow cells (8 X  107) 
2.9-5.1 
9.1-11.5 
* Normal cells were obtained from untreated  mice. ALS spleen cells were obtained from 
mice 24 hr after the last of four successive daily subcutaneous injections of ALS (0.5 ml each 
time).  The figures  in parentheses  indicate  the number  of cells injected  on  each occasion. 
SRBC were given as 0.5 ml of a 2% suspension. 
:~ Titers expressed in terms of log2 of their reciprocals. 
and  Marrow  Cells from  ALS-Treated  and  Untreated  Donors.--The  next  two 
experiments  were  performed  in  order  to  see what  effect,  if  any,  ALS  had  on 
the immunological competence of cells located within the thymus  and marrow. 
CY-treated  mice  were  given  SRBC  and  mixtures  of  syngeneic  thymus  and H.  S.  JEEJEEBHO¥  969 
marrow cells from untreated mice and from mice previously given ALS. Table 
V shows that ALS treatment had no effect on the immunological competence 
of cells located within the thymus, and that marrow cells were only slightly 
affected.  Moreover,  the  second  experiment  in  Table V  shows  that  the  de- 
pressed hemagglutinln titers produced by CY-treated mice given SRBC  and 
spleen cells from ALS-treated donors could be elevated to normal levels by 
injections of thymus  and marrow cells from the  same ALS-treated animals. 
TABLE  V 
Hemagglutinin Titers Produced by Cydophosphamide (CY)-Treated C57BL/6J Mice Given 
SRBC and Mixtures of Syngeneic Thymus and Marrow Cells  from 
Untreated and ALS-Treated Animals 
Hemagglutinin titers:t  Experi-  No. of 
ment  CY treated hosts received SRBC and*  recipients  Mean  95% confidence 
no.  limits of means 
Normal  thymus cells (8 X  10 7)  q-  normal marrow  8  7.8  6.9-8.7 
cells (8 X  10 7) 
ALS  thymus  ceils  (8  X  10 7)  q-  normal  marrow  8  7.3  6.8-7.8 
cells (8 X  10 7) 
Normal  thymus  cells  (8  X  10 7)  -q-  AIrS  marrow  8  6.4  5.7-7.1 
cells (8 X  10 7) 
Normal spleen cells (2  X  10 7)  8  9.0  8.3-9.7 
ALS spleen cells (2 X  10 7)  8  3.8  2.9-4.7 
ALS  thymus cells  (8  X  10 7)  +  ALS  marrow  cells  7  5.5  4.7-6.3 
(8 X  10 7) 
ALS spleen cells (2 X  10 7) q- ALS thymus (8 X  10 r)  8  8.6  7.9-9.3 
and ALS marrow cells (8 X  10 7) 
* Normal cells were obtained from untreated  mice and ALS  cells from mice 24 hr after 
the last of four successive daily subcutaneous injections of ALS  (0.5 ml each time).  In Ex- 
periment 2,  the ALS  spleen,  thymus,  and marrow cells were obtained from  the same ALS- 
treated animals.  SRBC  given as 0.5 ml of a  2% suspension. 
J; Titers expressed in terms of log2 of their reciprocals. 
DISCUSSION 
Hemagglutinin  titers  produced  by  CY-treated  mice  given  SRBC  and  a 
mixture  of  normal  thymus  and  marrow  cells  were  always  higher  than  the 
sum of the titers which were produced by the groups given SRBC and normal 
thymus cells or marrow cells alone in that same experiment. These findings are 
in  agreement with  observations  made  by  Claman  et  al.  (7)  and  others  (8) 
which have shown that  the production of antibody to SRBC  requires a syn- 
ergistic  interaction between cells  of  thymus and marrow origin. In addition, 
the present experiments show that this synergism can be demonstrated when 
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been  rendered  immunoIogically anergic  by prior  treatment  with  CY instead 
of the X-irradiation used by previous workers (7,  8). 
It was necessary to inject the  CY-treated mice with  SRBC  and a  mixture 
containing 1.2  X  l0 s normal thymus cells and 1.2  X  l0 s normal marrow cells 
to obtain serum hemagglutinin levels similar to those which were found when 
the  mice received  SRBC  and  2  X  10  7 normal  spleen  cells.  It is  difficult  to 
explain  satisfactorily  why  such  large  numbers  of  thymus  and  marrow  cells 
were needed. Perhaps cells which  are involved in antibody production form a 
smaller proportion of the  thymus  and marrow cell populations  than  they do 
of the spleen cell population. Another possibility is that cells which are located 
within the thymus and marrow might require a period of residence maturation 
and,  possibly,  differentiation  in  another  environment  before  achieving  their 
full potential as participants in the immune response. 
The present experiments confirm previously reported observations (2,  3,  5, 
6, 9) which have shown that administration of ALS prior to injection of SRBC 
significantly depresses  the  ability of  treated  animals  to  produce  anti-SRBC 
antibody. The ALS used was absorbed with SRBC  prior to use. In addition, 
normal  horse  serum  was  completely ineffective  in  suppressing  the  immune 
response to SRBC and this serum was the preimmunization serum of the horse 
used for production  of ALS.  Hence,  it is unlikely  that  the  depression  of the 
immune response to  SRBC  by this ALS  could have been due to  the passive 
transfer of anti-SRBC antibodies,  as suggested by Guttman et al. (16). 
It has been shown that administration of ALS decreases the ability of cells 
in the lymph nodes and spleen to participate in immune responses (9,  17,  18). 
Similar results have been obtained in  this present series of experiments. Ad- 
ministration  of  ALS  significantly  decreased  the  ability  of  spleen  cells  from 
treated  animals  to produce  anti-SRBC  antibody when  they were  adoptively 
transferred  with  SRBC  to mice given  CY.  Tables I  and III show  that  this 
decrease  in  the  immunological  competence  of  spleen  cells  was  only  demon- 
strable when the  amount of ALS given was sufficient to depress the animal's 
immune response to SRBC. 
Hemagglutinin  titers  produced by CY-treated mice given SRBC  and  2  X 
l07 normal spleen cells were always much higher than those which were found 
when  the spleen cells were  obtained from ALS-treated mice. Titers could be 
raised to the levels found in the former group if CY-treated recipients of SRBC 
and  spleen  cells  from ALS-treated  donors  were  also  injected  with  mixtures 
containing  normal  thymus  and  marrow  cells.  Inocula which  contained  only 
marrow cells were completely ineffective while thvmus cells alone were much 
less  effective than  mixtures  containing  both  thynms  and  marrow  cells.  The 
ability of  a  mixture of thymus  and marrow cells  to  restore  titers  to normal 
levels could not have been due to a simple additive effect, as a synergistic inter- 
action  was  regularly  demonstrable  between  spleen  cells  from  ALS-treated H.  S.  JEEJEEBtIOY  971 
donors on the one hand,  and normal thymus and marrow cells on the other. 
The work of Micklem et al. (19) and of Globerson and Auerbach (20) suggests 
that the spleen contains a mixture of cells which have originated in the thymus 
and marrow. If this is so,  our results would suggest that immunosuppression 
by ALS  is  associated  with  the  inactivation  of  both  thymus-  and  marrow- 
derived lymphocytes. 
Inactivation  of  thymus-derived lymphocytes by ALS  would  explain  why 
recovery from the  effects of ALS is  thymus-dependent  (2,  12,  21)  and why 
treatment with ALS depletes the thymus-dependent areas of the lymph nodes 
and  spleen  (22-24).  The possibility  that  cells,  other  than  those  of  thymus 
origin, might also be inactivated as the result of treatment with ALS is  one 
interpretation of findings reported by Mitchison  (25). This possibility is  also 
suggested  by  the  failure  of  Levey and  Medawar  (4)  to  demonstrate  any 
curtailment of allograft survival when mice were given 2 X  10  s~ thymus cells, 
25  days after skin grafting. On the other hand,  Gray et al. (3)  were able to 
show  a  significant  reduction  in  allograft  survival  times  when  ALS-treated 
mice were given 108 syngeneic spleen cells. It has been recently shown by Luba- 
roff (26) that cells of marrow origin play an important role in allograft rejection. 
These observations, together with those of Gray et al.  (3), suggest that allo- 
graft survival times were not decreased when ALS-treated animals  received 
thymus cells alone (4) because the animals might  also have been deficient in 
marrow-derived lymphocytes. 
Inactivation of marrow-derived spleen cells by ALS was not demonstrable 
in experiments reported by Martin and Miller (9). They showed that thymus 
cells alone could raise the peak PFC response of irradiated recipients of SRBC 
and spleen cells from ALS-treated donors to levels found when the  animals 
were given SRBC and normal spleen cells. There were differences between their 
experiments and those reported in this paper,  and any one or more of these 
differences might  have  been  responsible for  their failure  to  show  that  ALS 
inactivates cells of marrow origin. The use of irradiation rather  than  CY to 
depress the immune responses of the recipients of adoptively transferred spleen 
cells was  probably not  a  factor of much  importance.  However, in  order  to 
quantitate  anti-SRBC  antibody  production  by  the  transferred  cells  they 
measured the PFC responses in the spleens of the recipient animals rather than 
their  serum  hemagglutinin  levels.  The former measures  early  19S  antibody 
production while the  latter  is  predominantly a  7S  antibody response to im- 
munization with SRBC. Perhaps more important was that the amount of ALG 
given to their donor mice, though immunosuppressive, still allowed considerable 
numbers  of PFC  to be produced when given to other mice which were sub- 
sequently immunized with  SRBC.  In  our experiments,  the  amount  of ALS 
given to the donor mice was more strongly immunosuppressive. Administration 
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of  treated  animals  to  background  levels.  A  subsequent  communication will 
show that when mice are given ALS, the first cells to be inactivated are those 
of  thymus  origin.  Deficiencies  of  marrow-derived  spleen  cells  only  become 
evident when strongly immunosuppressive amounts of ALS are administered. 
The ability of ALS to inactivate marrow-derived spleen cells,  as described 
in  these present  experiments,  could not have been due  to  the fact that  the 
horse  used  for  preparation  of ALS  had  been  immunized  with  inocula  con- 
taining thymus and lymph node cells and therefore, presumably, cells of both 
thymus  and marrow origin. Inactivation of marrow-derived spleen cells was 
also demonstrable (our unpublished findings)  when mice received ALS which 
had  been  prepared  by  immunizing  horses  with  mouse  thymus  cells  alone. 
Studies  with  radioactively labeled ALS  IGG  (27)  have  shown  that  anti- 
lymphocyte  antibody  fails  to  penetrate  lymphoid  tissue  to  any  significant 
degree. The present functional studies  are  in  agreeraent with  these observa- 
tions. They show that administration of ALS does not alter the immunological 
competence of cells located within the thymus and that cells in the bone mar- 
row  are  only affected to  a  slight  degree.  In  contrast,  administration  of im- 
munosuppressive  doses  of ALS  markedly  decreases  antibody production by 
spleen cells.  It has been shown by Cantor et al.  (28)  that the majority of im- 
munologically competent cells  in  the  spleen are  derived from the  peripheral 
recirculating pool of lymphocytes. Hence our findings are consistent with the 
generalization (17, 27, 29) that the principal site of action of ALS is the periph- 
eral recirculating lymphocyte. 
It  is  difficult to  explain  satisfactorily why cells  in  the  thymus  and  bone 
marrow are relatively imnmne to the effects of ALS, since in vitro incubation 
with ALS can be shown to decrease the ability of thymus cells to participate in 
immune  responses.  Agglutinating  and  cytotoxic antibody  titers  of ALS  are 
approximately similar regardless of whether cells from mouse thymus, marrow, 
lymph node, or spleen are used as target cells  and this suggests that approxi- 
mately similar numbers of antibody binding sites are present on each of these 
different lymphoid cell types. Differences in avidity for antibody, as between 
central and peripheral lymphoid cells,  is also unlikely to account for the rela- 
tive immunity of cells in the thymus and marrow. With large doses of ALS we 
have been able to show (unpublished observations) that, despite the presence 
of free ALS in the circulation,  the immunological competence of cells  in the 
thymus and, to a lesser degree, in the marrow, remain unaffected. 
Finally, the second experiment in Table V suggests that the unaffected cells 
within the thymus and marrow could provide a mechanism for recovery from 
the effects of ALS. This would explain why the immunosuppressive properties 
of ALS can be so markedly potentiated by prior thymectomy (2,  12,  21)  or 
irradiation (4) of the recipient. H.  F.  JEEJEEBEOY  973 
SUMMARY 
When  CY-treated mice were given sheep red blood cells the serum hemag- 
glutinin titers produced were significantly lower than those found when mice 
received SRBC but not CY. Titers could be raised to the levels found in the 
latter group if,  in addition  to SRBC,  the  CY-treated mice received 2  X  107 
normal syngeneic spleen cells or a mixture containing 1.2 X  10  ~ normal thymus 
and 1.2  X  10  s normal marrow cells.  Inocula which contained fewer cells pro- 
duced correspondingly smaller amounts of antibody. A  synergistic interaction 
between normal thymus and marrow cells was always demonstrable in these 
experiments. 
Hemagglutinin titers produced by CY-treated mice given SRBC  and  2  X 
107 normal syngeneic spleen cells were always much higher  than those found 
when the spleen cells were obtained from animals previously given ALS. Titers 
could be raised  to normal levels if the  animals in  this  latter group received 
additional  injections  containing  mixtures  of  normal  syngeneic  thymus  and 
marrow  cells.  Marrow  cells  alone were  completely ineffective,  while  inocula 
which  only contained thymus cells were much less effective than mixtures  of 
thymus and marrow cells. These results suggest  that  immunosuppression by 
ALS is associated with the inactivation of both thymus and  marrow-derived 
lymphocytes. 
In  other  experiments  CY-treated  mice  received  SRBC  and  mixtures  of 
thymus  and marrow cells from both untreated  and ALS-treated donors.  No 
decrease in the immunological competence of cells located within  the thymus 
of ALS-treated donors was demonstrable in  these  experiments.  Marrow cells 
were slightly affected but to a markedly lesser degree than were spleen cells of 
ALS-treated animals. In a  final experiment,  it was possible to show  that the 
thymus  and marrow cells  of ALS-treated animals  could  repair  the  immuno- 
logical defects which were present in their own spleen cell populations. 
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